Revenue Soars 20% but Profit Halts—a Margin Collapse Under Regulatory & Brownfield Drag

The numbers tell a story in conflict. Revenue grew ₹531 crore on the back of 14% bed capacity growth and 8% ARPP gains—a respectable volume story. But net profit fell ₹75 crore in the same period. That 36-basis-point gap between revenue growth and profit decline is not noise. It is a signal that margin pressure is structural, not cyclical.

EBITDA grew 18% YoY on strong operational momentum—H1 EBITDA up 17% to ₹1524 Cr. Yet profit fell. The breakdown: oncology revenue dropped to 21% of in-patient revenue from 26% YoY after CGHS discontinued high-value chemotherapy drugs. While a ₹200 Cr CGHS rate revision in Q2 offset the ₹100 Cr loss, the mix shift to lower-margin services is recurring. Brownfield facilities—Max Smart (260 beds), Saket complex, and the massive Sector 56 Gurgaon ramp (500 beds)—created pre-opening and ramp-up drag. Management estimates ₹40–50 Cr EBITDA loss at Gurgaon alone. The result: solid EBITDA growth but margin compression below that line from finance costs, higher tax burden, and payor mix degradation.

Brownfield drag quantified: Management was explicit on greenfield EBITDA losses for the first time. Gurgaon Sector 56 (500 beds) expected to loss ₹40–50 Cr at ramp, similar to the ₹30 Cr drag Dwarka absorbed at 300-bed rollout. This is material and will persist through FY28 as the pipeline (Pune 450 beds, Bhubaneswar 250 beds, Zirakpur 400 beds) comes online.

Oncology framed as mix shift: Rather than a one-time hit, the CGHS chemo discontinuation (₹100 Cr loss) was reframed as a structural payor-mix migration. Oncology fell to 21% of in-patient revenue from 26%, but the ₹200 Cr CGHS rate revision offset the loss. Management is transparent: the institutional (CGHS/ECHS/CCI) payor base will shrink as older hospitals are de-empanelled; newer brownfields will re-empanel at maturity and carry higher-margin private mix.

Expansion pipeline reaffirmed: No new facilities added, but ₹415 Cr capex was formally approved for 209 brownfield beds across Noida, Vaishali, and BLK-Max. 3000+ bed capacity target in 18–24 months remains intact. But phased commissioning is now acknowledged as the norm, not the exception.

The market's verdict is unambiguous: FII are exiting. Institutional ownership fell from 45.39% in Q4 FY26 to 41.78% in Q1 FY27—a 3.61 percentage-point reduction in one quarter. Simultaneously, DII ownership rose from 26.32% to 29.96%, a 3.64pp gain. This divergence—foreign investors reducing, domestic investors buying—signals institutional skepticism on the story while domestic retail/HNI believe in the long-term expansion thesis.

The stock reflects that skepticism. At ₹915, Max is trading 30.4% below its all-time high of ₹1314, and it sits below both the 50-day (₹941.52) and 200-day (₹1009.98) moving averages. The RSI is 54.3 (neutral), not oversold, suggesting the tape is consolidating rather than capitulating. Volume is normal. The 52-week range is ₹797–₹1185; the current price is closer to the bottom than the top, but the downtrend has not been challenged.

This price action confirms the fundamental read: the Q2 print (revenue +20%, PAT -16%) was seen as a miss on the profit side, not a miss on growth. The market is pricing in near-term margin pressure and waiting for proof that brownfield normalization and regulatory stabilization will restore profit growth. Until that proof arrives, the stock will likely trade in a range, accumulating domestic buyers on weakness but held back by FII skepticism.